Clinical Trials on Vector Borne Diseases in Australia

Total 13510 results

Medicines for Malaria Venture
Q-Pharm Pty Limited; Clinical Network Services (CNS) Pty Ltd; QIMR Berghofer...

Completed

Safety, Tolerability and Antimalarial Activity of Single Doses of OZ439 and PQP

Malaria

Australia
Merck Sharp & Dohme LLC

Recruiting

A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003)

Malaria

Australia
National Institute of Allergy and Infectious Diseases...

Completed

Phase 1 Study of the Safety, Reactogenicity, and Immunogenicity of AMA1-C1/ISA 720: Blood Stage Vaccine for Plasmodium Falciparum

Malaria

Australia
Medicines for Malaria Venture
Q-Pharm Pty Limited; Clinical Network Services (CNS) Pty Ltd; QIMR Berghofer...

Completed

Safety, Tolerability and Pharmacokinetic Profile of Ascending Oral Doses of MMV390048, Part A

Malaria

Australia
Medicines for Malaria Venture
Nucleus Network Ltd; Southern Star Research Pty Ltd.

Completed

MMV533 Plasmodium Falciparum Volunteer Infection Study

Malaria

Australia
Medicines for Malaria Venture
Q-Pharm Pty Limited; Clinical Network Services (CNS) Pty Ltd; QIMR Berghofer... and other collaborators

Completed

Effectiveness of OZ439 as a Gametocytocidal and Transmission Blocking Agent (OZGAM)

Malaria

Australia
Medicines for Malaria Venture
Nucleus Network Ltd; Southern Star Research Pty Ltd.

Completed

Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of Ruxolitinib With Artemether-lumefantrine

Malaria

Australia
Medicines for Malaria Venture
Q-Pharm Pty Limited; Clinical Network Services (CNS) Pty Ltd; QIMR Berghofer... and other collaborators

Completed

Experimental Falciparum Transmission to Anopheles (EFITA)

Malaria

Australia
GlaxoSmithKline

Terminated

A First Time in Human Study in Healthy Volunteers to Investigate a New Medicine to Treat Malaria

Malaria

Australia
Medicines for Malaria Venture
Q-Pharm Pty Limited; Clinical Network Services (CNS) Pty Ltd; QIMR Berghofer...

Completed

MMV390048 and Its Antimalarial Activity Against Plasmodium Falciparum in Healthy Adult Subjects, Part B

Malaria

Australia
Medicines for Malaria Venture
Q-Pharm Pty Limited; Clinical Network Services (CNS) Pty Ltd; QIMR Berghofer...

Completed

A Phase Ib Induced Malaria Infection Study With the Combination of OZ439 and DSM265 (OZ/DSMCombo)

Malaria

Australia
Medicines for Malaria Venture
Queensland Institute of Medical Research

Completed

Effectiveness of OZ439 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Volunteers

Malaria

Australia
sigma-tau i.f.r. S.p.A.
CPR Pharma Services Pty Ltd, Australia

Completed

Food Interaction Study on the Pharmacokinetics of Eurartesim™ (DHA and PQP)in Healthy Male Adult Volunteers

Malaria, Falciparum

Australia
Medicines for Malaria Venture
Nucleus Network Ltd; Southern Star Research Pty Ltd.

Completed

A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetic Profile of a Single Doses of MMV533.

Malaria

Australia
Medicines for Malaria Venture
Q-Pharm Pty Limited; Clinical Network Services (CNS) Pty Ltd; Queensland Institute...

Terminated

A Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in Healthy Subjects With Induced Blood Stage Plasmodium Falciparum or Plasmodium Vivax Infection (DSMOZ-2)

Malaria

Australia
sigma-tau i.f.r. S.p.A.
CPR Pharma Services Pty Ltd, Australia

Completed

A Pharmacokinetic (PK) Trial in Healthy Asian and Caucasian Volunteers Investigating the PK Profile of Eurartesim™

Malaria, Falciparum

Australia
Medicines for Malaria Venture
Q-Pharm Pty Limited

Terminated

MMV390048 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants

Malaria, Falciparum

Australia
Idorsia Pharmaceuticals Ltd.

Completed

Effect of ACT-451840 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Subjects

Healthy Subjects

Australia
Novartis Pharmaceuticals
Medicine for Malaria Venture

Terminated

Effectiveness of KAE609 in Reducing Asexual & Sexual Blood-stage P.Falciparum Infection & Infectivity to Mosquitos

Plasmodium Falciparum Malaria

Australia
Medicines for Malaria Venture
Q-Pharm Pty Limited; Clinical Network Services (CNS) Pty Ltd; QIMR Berghofer...

Completed

SJ733 Induced Blood Stage Malaria Challenge Study (SJ733IBSMCS)

Plasmodium Falciparum Malaria

Australia
Serum Institute of India Pvt. Ltd.
PPD

Completed

Safety Study of Dengushield in Healthy Adults

Dengue | Phase 1

Australia
Serum Institute of India Pvt. Ltd.
PPD Australia Pty Ltd

Completed

A Phase 1 Safety Study of Dengusiil in Healthy Adults

Prevention of Dengue Fever

Australia
Atea Pharmaceuticals, Inc.

Completed

Study of AT-752 in Healthy Subjects

Dengue

Australia
Medicines for Malaria Venture
QIMR Berghofer Medical Research Institute; Children's Health Queensland Hospital... and other collaborators

Completed

Pyronaridine in Healthy Adult Participants Infected With Blood Stage Malaria

Protozoan Infections | Malaria | Parasitemia | Malaria,Falciparum | Parasitic Disease | Malaria Recrudescence

Australia
Ology Bioservices

Completed

Additional 6-Month Safety Follow-up After Completion of Precursor Study 880801

Prophylaxis of Ross River Virus Infection

Australia
Ology Bioservices

Completed

Ross River Virus (RRV) Vaccine Study

Prophylaxis of Ross River Virus Infection

Australia
Elisabethinen Hospital
Baxter Healthcare Corporation; ASOKLIF

Unknown

Evaluation of Immunogenicity of Different Tick Borne Encephalitis (TBE) Fast Protective Traveler Schemes With Inactivated TBE Whole Virus Vaccine (immunisation)

Tick Borne Encephalitis

Austria, Czech Republic
Medicines for Malaria Venture
GlaxoSmithKline; ICON plc; QIMR Berghofer Medical Research Institute; Swiss BioQuant... and other collaborators

Completed

Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum

Pathologic Processes | Infections | Systemic Inflammatory Response Syndrome | Inflammation | Vector Borne Diseases | Parasitic Diseases | Protozoan Infections | Malaria | Parasitemia | Malaria,Falciparum | Anti-Infective Agents | Antimalarials

Australia
Medical University of Vienna
Austrian Science Fund (FWF)

Completed

Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients

Tick Borne Encephalitis

Austria
Medical University of Vienna

Completed

Humoral and Cellular Immunity of Low and High-responders After Tick-borne Encephalitis Vaccination

Tick-borne Encephalitis

Austria
Themis Bioscience GmbH

Completed

Zika-Vaccine Dose Finding Study Regarding Safety, Immunogenicity and Tolerability (V186-001)

Zika Virus

Austria
Medical University of Vienna

Unknown

Application of a TBE-Vaccine in Obese Persons

Tick Borne Encephalitis

Austria
Themis Bioscience GmbH

Completed

Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP (V187-001) (MV-ZIKA-RSP)

Zika Virus Infection

Austria
Sanofi

Completed

Study of Live Attenuated ChimeriVax™-Japanese Encephalitis Vaccine

Japanese Encephalitis

Australia
Pfizer

Completed

TBE Antibody Persistence and Booster Vaccination Study in Children and Adolescents (Follow-up to Study 209)

Encephalitis, Tick-Borne

Germany, Austria, Poland
Baxalta now part of Shire
Baxter Innovations GmbH

Completed

Phase 1/2 Lyme Vaccine Study

Prophylaxis of Lyme Borreliosis

Germany, Austria
Pfizer

Completed

Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children

Encephalitis, Tick-borne

Austria
Lyme Diagnostics Ltd.
Pharmahungary Group

Completed

Performance Evaluation of the DualDur In Vitro Diagnostic System in the Diagnosis of Lyme Borreliosis

Lyme Borreliosis

Austria, Czechia, Germany, Hungary, Poland, Slovakia
Pfizer

Completed

Tick-Borne Encephalitis (TBE) Seropersistence After First Booster and Response to a Second Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401)

Encephalitis, Tick-Borne

Austria, Germany, Poland
Pfizer

Completed

Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 Years

Encephalitis, Tick-borne

Austria
Sanofi

Completed

Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects

Dengue | Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus

Australia
Pfizer

Completed

Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children

Encephalitis, Tick-Borne

Austria, Czechia
Sanofi

Completed

A Study of ChimeriVax™-JE Live Attenuated Vaccine in Healthy Adults

Japanese Encephalitis | Encephalitis

Australia
Medical University of Vienna

Completed

TBE (Tick-borne Encephalitis) Vaccination in Allergic Patients

Vaccine Responsiveness in Allergy | Vaccine Responsiveness During Allergy De-sensitization Treatment

Austria
Themis Bioscience GmbH

Completed

Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine (MV-CHIK-202)

Chikungunya Virus Infection

Austria, Germany
Pfizer

Completed

Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years

Tick-borne Encephalitis

Austria, Germany, Poland
Sanofi

Completed

Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®)

Japanese Encephalitis | Yellow Fever

Australia
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia

Dengue Fever | Dengue Hemorrhagic Fever

Australia
Pfizer

Completed

FSME IMMUN NEW Follow-up to Study 199 in Children Aged 1 to 6 Years

Encephalitis, Tick-borne

Austria, Germany
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003)

Dengue Virus | Dengue Disease

United States, Australia, Canada, Finland, Germany, Israel, Taiwan

Clinical Trials on Vector Borne Diseases in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sweden

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations